Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan

BMC Infectious Diseases

Chang-Phone Fung²  Yung-Chieh Fu¹  Yu-Jiun Chan¹  Fu-Der Wang²  Yi-Tsung Lin² 

[1] Division of Microbiology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan

关键词: Tigecycline;    Klebsiella pneumoniae;    Clinical characteristics;    Bacteremia;    Antimicrobial resistance;   

Others  :  1135143
DOI  :  10.1186/1471-2334-14-1

 received in 2013-10-17, accepted in 2013-12-09,  发布年份 2014

【 摘 要 】

Background

Resistance among Klebsiella pneumoniae to most antibiotics is on the rise. Tigecycline has been considered as one of the few therapeutic options available to treat multidrug-resistant bacteria. We investigated the clinical and microbiological characteristics of tigecycline non-susceptible K. pneumoniae bacteremia.

Methods

Adult patients with tigecycline non-susceptible K. pneumoniae bacteremia at a medical center in Taiwan over a 3-year period were enrolled. K. pneumoniae isolates were identified by the E-test using criteria set by the US Food and Drug Administration (FDA). Data on the clinical features of patients were collected from medical records. Genes for β-lactamases, antimicrobial susceptibilities and pulsed-field gel electrophoresis (PFGE) results were determined for all isolates.

Results

Of 36 patients, 27 had nosocomial bacteremia. Overall 28-day mortality was 38.9%. The MIC₅₀ and MIC₉₀ of tigecycline were 6 and 8 mg/L, respectively. No carbapenemase was detected among the 36 isolates. Twenty isolates carried extended spectrum β-lactamases and/or DHA-1 genes. No major cluster of isolates was found among the 36 isolates by PFGE. Intensive care unit onset of tigecycline non-susceptible Klebsiella pneumoniae bacteremia was the only independent risk factor for 28-day mortality.

Conclusions

The high mortality of patients with tigecycline non-susceptible K. pneumoniae bacteremia may suggest a critical problem. Further study to identify the possible risk factors for its development and further investigation of this type of bacteremia is necessary.

【 授权许可】

   
2014 Lin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Meatherall BL, Gregson D, Ross T, Pitout JDD, Laupland KB: Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med 2009, 122(9):866-873.
• [2]Podschun R, Ullmann U: Klebsiella spp. As nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998, 11:589-603.
• [3]Lin YT, Chen TL, Siu L, Hsu SF, Fung CP: Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by Klebsiella pneumoniae in Taiwan. Eur J Clin Microbiol Infect Dis 2010, 29:1003-10.
• [4]Lin YT, Jeng YY, Chen TL, Fung CP: Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: clinical and microbiological characteristics in Taiwan, 2001–2008. BMC Infect Dis 2010, 10:307. BioMed Central Full Text
• [5]Tseng CP, Wu HS, Wu TH, Lin YT, Fung CP: Clinical characteristics and outcome of patients with community-onset Klebsiella pneumoniae bacteremia requiring intensive care. J Microbiol Immunol Infect 2013, 46:217-23.
• [6]Wu HS, Wang FD, Tseng CP, Wu TH, Lin YT, Fung CP: Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect 2012, 64:162-8.
• [7]Lin YT, Wang FD, Wu PF, Fung CP: Klebsiella pneumoniae liver abscess in diabetic patients: association of glycemic control with the clinical characteristics. BMC Infect Dis 2013, 13:56. BioMed Central Full Text
• [8]Keynan Y, Rubinstein E: The changing face of Klebsiella pneumoniae infections in the community. Int J Antimicrob Agents 2007, 30:385-9.
• [9]Livermore DM: Has the era of untreatable infections arrived? J Antimicrob Chemother 2009, (1):i29-36.
• [10]Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R: The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013, 41:110-6.
• [11]Rodríguez-Avial C, Rodríguez-Avial I, Merino P, Picazo JJ: Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect 2012, 18:61-6.
• [12]Daphnis E, Neonakis I, Stylianou K, Maraki S: First case of resistance to tigecycline by Klebsiella pneumoniae in a European University Hospital. Indian J Med Microbiol 2011, 29(1):78-9.
• [13]Tsai HY, Liao CH, Cheng A, Liu CY, Huang YT, Sheng WH, Hsueh PR: Emergence of tigecycline-resistant Klebsiella pneumoniae after tigecycline therapy for complicated urinary tract infection caused by carbapenem-resistant Escherichia coli. J Infect 2012, 65:584-6.
• [14]Roy S, Datta S, Viswanathan R, Singh AK, Basu S: Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007–10) and role of an efflux pump in tigecycline non-susceptibility. J Antimicrob Chemother 2013, 68:1036-42.
• [15]Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. Wayne, PA: CLSI: Document M100-S22; 2012.
• [16]Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF: In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 2008, 46:2862-7.
• [17]Ma L, Lu PL, Siu LK, Hsieh MH: Molecular typing and resistance mechanisms of imipenem-non-susceptible Klebsiella pneumoniae in Taiwan: results from the Taiwan surveillance of antibiotic resistance (TSAR) study, 2002–2009. J Med Microbiol 2013, 62:101-7.
• [18]Fang CT, Lai SY, Yi WC, Hsueh PR, Liu KL, Chang SC: Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 2007, 45:284-93.
• [19]Turton JF, Perry C, Elgohari S, Hampton CV: PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. J Med Microbiol 2010, 59:541-7.
• [20]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-83.
• [21]Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G: Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012, 18:54-60.
• [22]Qureshi ZA, Paterson DL, Peleg AY, Adams-Haduch JM, Shutt KA, Pakstis DL, Sordillo E, Polsky B, Sandkovsky G, Bhussar MK, Doi Y: Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases. Clin Microbiol Infect 2012, 18:887-93.
• [23]Huang TD, Berhin C, Bogaerts P, Glupczynski Y: In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline. J Antimicrob Chemother 2012, 67:2696-9.
• [24]Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, Themeli-Digalaki K, Tsakris A: Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant Gram-negative pathogens. J Clin Microbiol 2012, 50:3747-50.
• [25]Bolmström A, Karlsson Å, Engelhardt A, Ho P, Petersen PJ, Bradford PA, Jones CH: Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 2007, 45:2474-9.
• [26]Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y: Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56:2108-13.
• [27]Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M: Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-50.
• [28]Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordi E, Capozzi D, Balice MP, Tarasi A, Parisi G, Lappa A, Carattoli A, Petrosillo N , SEERBIO-GRAB network: High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013, 19:E23-E30.
• [29]Nigo M, Cevallos CS, Woods K, Flores VM, Francis G, Perlman DC, Revuelta M, Mildvan D, Waldron M, Gomez T, Koshy S, Jodlowski T, Riley W, Ruhe JJ: Nested case–control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:5743-6.